Navigation Links
Prostate Cancer Patients Benefit from New Zealand Center's Adoption of Elekta VMAT Radiotherapy Technique
Date:8/2/2010

AUCKLAND, New Zealand, Aug. 2 /PRNewswire/ – In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre (ARO) is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."

"When treating prostates, any internal organ motion or patient movement during the fraction is a problem," says John Simpson, Ph.D. chief physicist at ARO, New Zealand's first private radiation oncology center. "Some internal motion is inevitable, and patients are treated with a semi-full bladder at the start of treatment to push the colon upward and away from the radiation field to minimize its exposure. Prolonging treatment duration, therefore, both increases the probability of internal organ motion as well as external movement due to patient discomfort, both of which can hinder treatment accuracy. Adopting a technique that reduces treatment delivery time is an obvious benefit for these patients."

Elekta VMAT was an ideal solution for ARO's prostate cancer patients, who represent nearly one-third (approximately 20 patients) of the center's daily treatment volume of 70 to 80 patients. Since June 7, when the first patient began receiving Elekta VMAT therapy on ARO's Elekta Synergy® treatment system, eight additional patients have begun treatment courses and another two are awaiting therapy.

"Elekta VMAT is now our technique of choice for patients with prostate cancer," says Dr. Simpson, who leads a team that compared the arc therapy technique with its advanced image guided Intensity Modulated Radiation Therapy (IMRT) method. ARO physicists subjected Elekta VMAT to extensive quality assurance testing to ensure both delivery and plan quality were comparable to IMRT.

"It had to meet all the criteria we set for it," he says. "We were very pleased with the way SmartArc planning calculates Elekta VMAT and the way Elekta VMAT delivers the therapy. Intrafraction motion, dose conformance, treatment efficiency and patient comfort are all addressed—and in a few weeks we will attempt to increase prostate therapy volume by reducing the length of the treatment slot."

Currently, the complete prostate treatment session encompasses patient set-up, pre-treatment imaging and Elekta VMAT delivery (100 seconds) for a total of 20 minutes.

"We haven't decreased the treatment slot yet because we want to gain confidence that we will have interruption-free delivery," Dr. Simpson observes. "Once we have this confidence we can start to reduce the timeslots from 20 minutes to 15 minutes. Multiplied by 20 plus patients per day, we will gain an hour-and-a-half, which should help us add more timeslots to increase access to care."

ARO building advanced healthcare enterprise to serve Australasia

Since it opened two years ago, ARO has initiated a steady stream of technology acquisitions aimed at creating a state-of-the-art facility that will complement New Zealand's public health system.

Adding an extra degree of sophistication to ARO's operation, for example, is MOSAIQ®, Elekta's solution for oncology information management.

"We were determined to be paperless from day one, so MOSAIQ was the obvious choice to go along with the Elekta systems," he says. "MOSAIQ is the key component to our efficiency at ARO. We export our VMAT plans from our treatment planning system through MOSAIQ in the same way we do for any other conventional treatment without any additional steps."

ARO currently is embarking on a further advance in its treatment capability with the addition of a second VMAT capable Elekta Synergy system with a suite of add-ons to enable image guided stereotactic radiation therapy, which will begin in 2011.

About Elekta VMAT

With Elekta VMAT the treatment gantry—the part of the machine from which radiation beams originate—is in constant motion, with single or multiple gantry arc(s) sweeping around the patient. During these arc(s), the radiation intensity is continuously varied and modulated. This ensures a computer assisted delivery, according to the anatomical and tumor characteristics of the patient and the dose prescription. Using dynamic gantry arcs, Elekta VMAT can result in significantly reduced treatment times, while providing a more personalized treatment. In conventional "fixed gantry" therapy, the gantry makes several stops, which add to the overall treatment time and result in a longer session.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... The global preparative and process chromatography market ... from USD 5.49 billion in 2016, at a CAGR ... type, the preparative and process chromatography market is segmented ... process chromatography segment is expected to account for the ... Growth in this segment can primarily be attributed to ...
(Date:2/16/2017)... Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... announced that Vincent J. Angotti has ... of the company,s board of directors, effective Monday, ... decades of experience leading executive and commercial teams ...
(Date:2/16/2017)...   Spectralink Corporation , the global leader ... manufacturing and hospitality industries, today announced the results ... support features of its PIVOT™:SC (8744) ... study, conducted by The Tolly Group, showed quantifiable ... with dedicated hardware scanners. Spectralink introduced ...
Breaking Medicine Technology:
(Date:2/19/2017)... CA (PRWEB) , ... February 19, 2017 , ... ProBrand Glitch is a set of ... With ProBrand Glitch users can easily reveal any logo with a glitch reveal in just ... users control over the style and animation of each preset. Use these presets to add ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a ... Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed ... roof. Smiles by Seese serves patients of all ages with excellence in general, restorative, ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... ... ... Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, ... , What are the critical reimbursement questions manufacturers should be asking before ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
Breaking Medicine News(10 mins):